National Bank of Canada
MBX

National Bank of Canada’s MBX Biosciences MBX Stock Holding History

National Bank of Canada’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$607 Buy
+11
New +$384 ﹤0.01% 2828

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

National Bank of Canada's MBX Position: Q2 2026 in Review

National Bank of Canada opened a new position in MBX Biosciences (MBX) in Q2 2026: 11 shares worth $607. The stake represents ﹤0.01% of the portfolio and ranks #2828 among its holdings.

173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • National Bank of Canada held 11 shares of MBX Biosciences worth $607 as of Q2 2026.
  • MBX Biosciences was a new National Bank of Canada position in Q2 2026.
  • MBX Biosciences made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2828 holding.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.